Have a personal or library account? Click to login
Case report and review: alloimmunization, delayed hemolytic transfusion reaction, and clinically significant anti-Yta in a patient with ²-thalassemia/sickle cell anemia Cover

Case report and review: alloimmunization, delayed hemolytic transfusion reaction, and clinically significant anti-Yta in a patient with ²-thalassemia/sickle cell anemia

Paid access
|Dec 2020

References

  1. 1. Davis JR, Vinchinsky E, Lubin BH. Current treatment of sickle cell disease. Curr Prob Pediatr 1980;10:1–8.10.1016/S0045-9380(80)80007-7
  2. 2. Koshy M, Burd L, Wallace D, et al. Prophylactic red cell transfusions in pregnant patients with sickle cell disease. N Engl J Med 1988;319:1447–52.10.1056/NEJM1988120131922043054555
  3. 3. Walker RH, ed. Technical manual. 10th ed. Arlington, VA: American Association of Blood Banks; 1990:539–40.
  4. 4. Rodgers GP. Recent approaches to the treatment of sickle cell anemia. JAMA 1991;265:2097–101.10.1001/jama.1991.03460160075033
  5. 5. Milner PF, Squires JE, Larison PJ, Charles WT, Krauss JS. Posttransfusion crises in sickle cell anemia: role of delayed hemolytic reactions to transfusion. Southern Med J 1985; 78: 1462–9.10.1097/00007611-198512000-000164071176
  6. 6. Charache S. Problems in transfusion therapy (editorial). N Engl J Med 1990;322:1666–8.10.1056/NEJM1990060732223092342526
  7. 7. Ballas SK, Sherwood WC. Rapid in vivo destruction of Yt(a+) erythrocytes in a recipient with anti-Yta. Transfusion 1977;17:65-610.1046/j.1537-2995.1977.17177128889.x841677
  8. 8. Levy GJ, SelSet G, McQuisten D, et al. Clinical significance of anti-Ytb: report of a case using a 51chromium red cell survival study. Transfusion 1988;28:265–7.10.1046/j.1537-2995.1988.28388219157.x3285526
  9. 9. Giles CM, Metaxas MN. Identification of the predicted blood group antibody anti-Ytb. Nature 1964;202:1122–4.10.1038/2021122a014207215
  10. 10. Levene C, Bar-Shany S, Manny N, Moulds JJ, Cohen T. The Yt blood groups in Israeli Jews, Arabs, and Druse. Transfusion 1987;27:47–14.10.1046/j.1537-2995.1987.27688071697.x3686656
  11. 11. AuBuchon JP, Brightman A, Anderson JH, Kim B. An example of anti-Yta demonstrating a change in its clinical significance. Vox Sang 1988;55:171–5.
  12. 12. Person HA. Vertrees KM. Site of binding of chromium 51 to haemoglobin. Nature 1961; 189:1019–20.10.1038/1891019a013733788
  13. 13. McCurdy PR. 32DFP and 51Cr for measurement of red cell life span in abnormal hernoglobin syndromes. 1969;33:214–17.
  14. 14. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Luhin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617–21.10.1056/NEJM199006073222301
  15. 15. Orlina AR, Unger PJ, Koshy M. Posttransfusion alloimmunization in patients with sickle cell disease. Am J Hematol 1978;5:101–6.10.1002/ajh.2830050204
  16. 16. Coles SM. Klein HG. Holland PV. Alloimmunization in two multitransfused patient populations. Transfusion 1981; 21:462-610.1046/j.1537-2995.1981.21481276005.x
  17. 17. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. Blood 1990;76;1431–7.10.1182/blood.V76.7.1431.1431
  18. 18. Luban NLC. Variability in rates of alloimmunization in different groups of children with sickle cell disease: effect of ethnic background. Am J Pediatr Hem/Oncol 1989;11:314–19.
  19. 19. Alarif L, Castro O, Ofosu M, Dunston G, Scott RB. HLA-B35 is associated with red cell alloimmunization in sickle cell disease. Clin lmmuno lmmunopathol 1986;38:178–83.10.1016/0090-1229(86)90136-4
  20. 20. Michail-Merianou V, Pamphili-Panouspoulou L, Piperi-Lowes L, Pelegrinis E, Karaklis A. Moimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sang 1987;52:95–8.10.1111/j.1423-0410.1987.tb02999.x3300026
  21. 21. Amhruso DR, Githens JH, Alcorn R, Dixon DJ, Brown LJ, Vaughn WM, Hays T. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987;27:94–8.10.1046/j.1537-2995.1987.27187121485.x3810834
  22. 22. Paten E, Patel Soto B, Gayle R. Transfusion management of patients with sickle cell disease. Ann NY Acad Sci 1989; 565:446–8.10.1111/j.1749-6632.1989.tb24220.x
  23. 23. Blumberg N, ROSS K, Aliva E, Peck K. Should chronic transfusion be matched for antigens other than ABO and Rho(D)? Vox Sang 1984;47:205–8.
  24. 24. Beattie KM, Shafer AW. Broadening the base of a rare donor program by targeting minority populations. Transfusion 1986;26:401–4.10.1046/j.1537-2995.1986.26587020111.x3765029
  25. 25. Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485–9.10.1001/archinte.1988.00380110115024
  26. 26. Moore SB, Taswell HF, Pinea AA, Sonnenherg CL. Delayed hemolytic transfusion reactions: evidence of the need for an improved pretransfusion compatibility test. Am J Clin Pathol 1980;74:947.10.1093/ajcp/74.1.947395821
  27. 27. Diamond WJ, Brown FL, Bitterman P, Klein HG, Davey RJ, Winslow RM Delayed hemolytic transfusion reaction presenting a sickle-cell crisis. Ann Int Med 1980;93:231–3.10.7326/0003-4819-93-2-2317406372
  28. 28. Solanki D, McCurdy PR. Delayed hemolytic transfusion reactions. JAMA 1978;239:729–31.10.1001/jama.1978.03280350053013
  29. 29. Bove J. Delayed complications of transfusion. Conn Med J 1968;32:38.
  30. 30. Rao KRP, Patel AR Delayed hemolytic transfusion reactions in sickle cell anemia. Southern Med J 1989;82:1034–6.10.1097/00007611-198908000-000252762885
DOI: https://doi.org/10.21307/immunohematology-2019-1025 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Language: English
Page range: 102 - 104
Published on: Dec 14, 2020
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2020 C.D. Hillyer, J.M. Hallk, O. Tiegermaannd, E.M. Berkman, published by American National Red Cross
This work is licensed under the Creative Commons License.